Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2012

View Archived Issues

Johnson & Johnson presents highlights of third quarter 2012

Recent clinical data support approval of canagliflozin

Gene polymorphism linked to acute lung injury in Gram-negative sepsis

Tocilizumab shows positive effects in patients with neuromyelitis optica

Novel PI3K and mTOR inhibitors patented by Pathway Therapeutics

Abbott updates pipeline progress of third quarter 2012

New gamma-secretase modulators prepared at Pfizer

Chugai presents interim phase II results for CH-5424802

Prozymex presents new DPP-I inhibitors

CHMP recommends approval of Krystexxa

New agents for bacterial infections synthesized by Actelion Pharmaceuticals

Natco Pharma prepares new salts of anticancer agent

Actelion submits macitentan NDA

Amgen patents novel pim inhibitors

A novel marker can predict the outcome in osteosarcoma

Alnylam and Genzyme form RNAi therapeutics alliance in Asia

NXT-182 prevents neuronal apoptosis in vitro and increases neurogenesis in vivo

Health Canada approves new drug submission for Cinryze

Derma Sciences to begin phase III DSC-127 program

Astellas Pharma launches Myrbetriq in U.S.

Kaken submits application in Japan for topical antifungal agent

Eisai obtains FDA approval for Fycompa

Ono and Domain Therapeutics enter GPCR collaboration

Health Canada approves Seebri Breezhaler for COPD

Ligand to receive milestone payment from Merck & Co.

Phase I trial of Kevetrin now active

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...